Abstract:As a key component in combination therapy for acquired immunodeficiency syndrome (AIDS), non-nucleoside reverse transcriptase inhibitors (NNRTIs) have been proven to be an essential way in stopping HIV-1 replication. In the present work, in silico studies were conducted on a series of 119 NNRTIs, including 1-(2-hydroxyethoxymethyl)-6-(phenylthio)thymine (HEPT) and dihydroalkoxybenzyloxopyrimidine (DABO) derivatives by using the comparative molecular field analysis (CoMFA), comparative molecular similarity indices analysis (CoMSIA), docking simulations and molecular dynamics (MD). The statistical results of the optimal model, the ligand-based CoMSIA one (Q 2 = 0.48, R ncv 2 =0.847, R pre 2 = 0.745) validates its satisfactory predictive capacity both internally and externally. The contour maps, docking and MD results correlate well with each other, drawing conclusions as follows: 1) Compounds with bulky substituents in position-6 of ring A, hydrophobic groups around position- 1, 2, 6 are preferable to the biological activities; 2) Two hydrogen bonds between RT inhibitor and the Tyr 318, Lys 101 residues, respectively, and a π-π bond between the inhibitor and Trp 188 are formed and crucial to the orientation of the active conformation of the molecules; 3) The binding pocket is essentially hydrophobic, which are determined by residues such as Trp 229, Tyr 318, Val 179, Tyr 188 and Val 108, and hydrophobic substituents may bring an improvement to the biological activity; 4) DABO and HEPT derivatives have different structures but take a similar mechanism to inhibit RT. The potency difference between two isomers in HEPTs can be explained by the distinct locations of the 6-naphthylmethyl substituent and the reasons are explained in details. All these results could be employed to alter the structural scaffold in order to develop new HIV-1 RT inhibitors that have an improved biological property. To the best of our knowledge, this is the first report on 3D-QSAR modeling of this series of HEPT and DABO NNRTs. The QSAR model and the information derived, we hope, will be of great help in presenting clear guidelines and accurate activity predictions for newly designed HIV-1 reverse transcriptase (RT) inhibitor.

Studies of Relationship Between Biological Activities and HIV Reverse Transcriptase Inhibitors by Multivariate Adaptive Regression Splines with Curds and Whey

Multivariate adaptive regression splines?studies of HIV reverse transcriptase inhibitors

Evaluation of Novel HIV-1 Protease Inhibitors with DRV-resistance by Utilizing 3D-QSAR Molecular Docking and Molecular Dynamics Simulation

Docking, Molecular Dynamics and Quantitative Structure-Activity Relationship Studies for HEPTs and DABOs As HIV-1 Reverse Transcriptase Inhibitors

Proteochemometric Modeling Of The Bioactivity Spectra Of Hiv-1 Protease Inhibitors By Introducing Protein-Ligand Interaction Fingerprint

Screening Novel HIV-1 Protease Inhibitors Based on the Substrate Envelope Hypothesis

Unveiling Novel HIV-1 Protease Inhibitors Through an Integrated Analysis of 3D-QSAR, Molecular Docking, and Binding Free Energy

Classification and Regression TreesStudies of HIV Reverse Transcriptase Inhibitors

Molecular modeling studies of dihydro-alkyloxy-benzyl-oxopyrimidines (DABOs) as non-nucleoside inhibitors of HIV-1 reverse transcriptase using 3D-QSAR, Topomer CoMFA and molecular docking simulations

Revealing the Mutation Patterns of Drug-Resistant Reverse Transcriptase Variants of Human Immunodeficiency Virus through Proteochemometric Modeling

Docking Field-Based QSAR and Pharmacophore Studies on the Substituted Pyrimidine Derivatives Targeting HIV-1 Reverse Transcriptase

Quantitatives Structure-Activity Relationship and Modification of HIV Protease Inhibitors

Elucidating the Inhibiting Mode of AHPBA Derivatives Against HIV-1 Protease and Building Predictive 3D-QSAR Models

Systematic Investigation on Interactions for HIV Drug Resistance and Cross-Resistance among Protease Inhibitors

Three dimensional quantitative structure-activity relationship of DATA analogues as HIV-1 reverse transcriptase inhibitors

Multiple Molecular Dynamics Simulations and Free-Energy Predictions Uncover the Susceptibility of Variants of HIV-1 Protease against Inhibitors Darunavir and KNI-1657

QSAR Models for 2-Amino-6-arylsulfonylbenzonitriles and Congeners HIV-1 Reverse Transcriptase Inhibitors Based on Linear and Nonlinear Regression Methods.

Support Vector Machine (SVM) Models for Predicting Inhibitors of the 3' Processing Step of HIV-1 Integrase

Identifying Selections Operating on HIV-1 Reverse Transcriptase via Uniform Manifold Approximation and Projection

Proposal of pharmacophore model for HIV reverse transcriptase inhibitors: Combined mutational effect analysis, molecular dynamics, molecular docking and pharmacophore modeling study

Multi-target QSAR study in the analysis and design of HIV-1 inhibitors